 |
 |
|
|
RESÚMENES SEPTIEMBRE 2008 |
Schizophrenia-Psychotic Disorders & Antipsychotics
(Haga un click en la
información del journal para acceder al resúmen)
5 – doble-ciego o
metanálisis; 4 – subanálisis o simple ciego; 3 –
revisión, abierto, básico; 2 – casos; 1 – opinión
GRATIS = Texto gratuito en algunos países de la región iberoamericana
(algunos artículos requieren ir a la tabla de contenidos del
número actual de la revista)
3 - Role of glutamate in schizophrenia: integrating
excitatory avenues of research
Monsheel Sodhi, Kimberly H Wood and James Meador-Woodruff
Expert Review of Neurotherapeutics. September 2008, Vol. 8, No. 9, Pages 1389-1406
4< - An economic evaluation of aripiprazole
vs olanzapine adapted to
the Italian setting using outcomes of metabolic syndrome and risk for diabetes
in patients with schizophrenia
Giorgio L Colombo,
Mauro Caruggi, Sergio Di Matteo, Alessandro Rossi
Neuropsychiatric Disease and Treatment. ON-LINE EARLY.
September 2008
GRATIS 5 - Double-blind, randomized trial comparing efficacy and
safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with
schizophrenia or schizoaffective disorder
Walter Deberdt, Ilya Lipkovich,
Alexandra N Heinloth, Lin Liu, Sara Kollack-Walker, Sara E Edwards, Vicki Poole Hoffmann,
Thomas A Hardy
Therapeutics and Clinical Risk Management. Issue 4. September 2008
3! - Reduced plasma nitric oxide metabolites before and
after antipsychotic treatment in patients with schizophrenia compared to
controls
Bun-Hee Lee and Yong-Ku Kim
Schizophrenia
Research. Volume 104, Issues 1-3,
September 2008, Pages 36-43
3 - Insulin resistance following continuous, chronic olanzapine treatment: An animal model
Araba F. Chintoh,
Steve W. Mann, Tony K.T. Lam, Adria Giacca and
Gary Remington
Schizophrenia
Research. Volume 104, Issues 1-3, September 2008, Pages
23-30
3! - A comparison of schizophrenia outpatients treated
with antipsychotics with and without metabolic syndrome: Findings from the
CLAMORS study
Celso Arango,
Julio Bobes, Pedro Aranda,
Rafael Carmena, Margarida Garcia-Garcia, Javier Rejas and on
behalf of the CLAMORS Study Collaborative Group
Schizophrenia
Research. Volume 104, Issues 1-3, September 2008, Pages 1-12
3 - Neurological abnormalities and cognitive ability in
first-episode psychosis
Paola Dazzan,
Tuhina Lloyd, Kevin D. Morgan, Jolanta Zanelli, Craig Morgan, Ken Orr, Gerard
Hutchinson, Paul Fearon, Matthew Allin, Larry Rifkin, Philip K. McGuire,
Gillian A. Doody, John Holloway, Julian Leff, Glynn Harrison, Peter B. Jones, Robin M. Murray
The British Journal of Psychiatry (2008) 193:
197-202
3 - Adjunctive galantamine, but
not donepezil, enhances the antipsychotic-like effect
of raclopride in rats
Charlotte
Wiker, Björn Schilström, Carina Sandbäck, Marie-Louise Wadenberg and Torgny H. Svensson
The International Journal of Neuropsychopharmacology (2008),
11 : 845-850
3! - The
effects of antipsychotics on the density of cannabinoid
receptors in the dorsal vagal complex of rats:
implications for olanzapine-induced weight gain
Katrina Weston-Green,
Xu-Feng Huang, Mei Han and Chao Deng
The International Journal of Neuropsychopharmacology, 2008,
11 : 827-835
3 - Striatal D2/D3 Receptor
Occupancy, Clinical Response and Side Effects with Amisulpride:
An Iodine-123-Iodobenzamide SPET Study
E. M. Meisenzahl, G. Schmitt, G. Gründer, S. Dresel, T. Frodl,C. la Fougère, J. Scheuerecker, M. Schwarz, R. Boerner,J. Stauss, K. Hahn, H.-J. Möller
Pharmacopsychiatry 2008;
41: 169-175
3 - Emerging
drugs for schizophrenia
Ofer Agid
, Shitij Kapur & Gary Remington
Expert Opinion on Emerging Drugs. September 2008, Vol. 13, No. 3, Pages 479-495
3 - Heart Rate Variability in Schizophrenic Patients
Switched from Typical Antipsychotic Agents to Amisulpride
and Olanzapine. 3-Month Follow-Up
Ying-Chieh Wang,
Cheryl C.H. Yang, Ya-Mei Bai,
Terry B.J. Kuo
Neuropsychobiology 2008;57:200-205
3! - Spatial working memory and problem solving in
schizophrenia: The effect of symptom stabilization with atypical antipsychotic
medication
Peter J. Snyder, Colleen E. Jackson, Danijela Piskulic, James Olver, Trevor Norman and
Paul Maruf
Psychiatry Research. Volume 160, Issue 3, 30 September 2008, Pages 316-326
3 - The influence of 5-HT2C and MDR1 genetic polymorphisms on
antipsychotic-induced weight gain in female schizophrenic patients
Martina Rojnic Kuzman, Vesna Medved,
Nada Bozina, Ljubomir Hotujac, Ivica Sain and Hrvoje Bilusic
Psychiatry Research. Volume 160, Issue 3, 30 September 2008, Pages 308-315
3 - A 12-month follow-up study of treating overweight
schizophrenic patients with aripiprazole
S. G. Schorr, C. J. Slooff, R. Postema, W. Van Oven, M. Schilthuis, R. Bruggeman, K. Taxis
Acta Psychiatrica Scandinavica. Volume 118 Issue
3, Pages 246 - 250
3! - Rates and predictors of remission and recovery during
3 years in 392 never-treated patients with schizophrenia
M. Lambert, D. Naber, A. Schacht, T. Wagner, H.-P. Hundemer, A. Karow, C. G. Huber, D. Suarez, J. M. Haro, D. Novick, R. W. Dittmann, B. G.Schimmelman
Acta Psychiatrica Scandinavica. Volume 118 Issue
3, Pages 220 - 229
3! - Twins discordant for schizophrenia: psychopathology
of the non-schizophrenic co-twins
S. V. Argyropoulos, S. Landau, S. Kalidindi, T. Toulopoulou, D. J. Castle, R. M. Murray, M. M. Picchion
Acta Psychiatrica
Scandinavica.
Volume 118 Issue 3, Pages 214 - 219
3 - Major psychoses with mixed psychotic and mood
symptoms: are mixed psychoses associated with different neurobiological
markers?
E. Bora, M. Yucel, A. Fornito, M. Berk, C. Panteli
Acta Psychiatrica Scandinavica.
Volume 118 Issue 3, Pages 172 - 187
GRATIS 3! -
Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of
clinically effective antipsychotics
Bernard Masri, Ali Salahpour, Michael Didriksen, Valentina Ghisi, Jean-Martin Beaulieu, Raul R. Gainetdinov, and Marc G. Caron
PNAS September
9, 2008 vol. 105 no. 36 13656-13661
GRATIS 3! - Clozapine and sulpiride but not
haloperidol or olanzapine activate brain DNA demethylation
E. Dong, M. Nelson, D. R. Grayson, E. Costa, and A. Guidotti
PNAS September 9, 2008 vol.
105 no. 36 13614-13619
3 - Impact of
Multiple Inhibitors or Substrates of Cytochrome P450
2D6 on Plasma Risperidone Levels in Patients on Polypharmacy
Mannheimer B, Bahr CV, Pettersson H, Eliasson E
Ther Drug Monit. 2008 Aug 23. [Epub ahead of print]
3! - Comparative remission rates of schizophrenic patients
using various remission criteria
Romain Beitinger,
Jingxia Lin, Werner Kissling and Stefan Leucht
3 - Bell-Shaped D-Serine
Actions on Hippocampal Long-Term Depression and
Spatial Memory Retrieval
Zhi Zhang, Neng Gong, Wei Wang, Lin Xu and Tian-Le Xu
Cerebral Cortex 2008
18(10):2391-2401
5 - Double-Blind Comparison of First- and
Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From
the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
Linmarie Sikich,
Jean A. Frazier, Jon McClellan, Robert L. Findling, Benedetto Vitiello, Louise Ritz, Denisse Ambler, Madeline Puglia, Ann E. Maloney, Emily
Michael, Sandra De Jong, Karen Slifka,
Nancy Noyes, Stefanie Hlastala, Leslie Pierson, Nora
K. McNamara, Denise Delporto-Bedoya, Robert Anderson,
Robert M. Hamer, and Jeffrey A. Lieberman
Am J Psychiatry Published September 15,
2008
GRATIS 4 - Early
evaluation of patient risk for substantial weight gain during Olanzapine treatment for schizophrenia, schizophreniform,
or schizoaffective disorder
Ilya Lipkovich , Jennie G Jacobson , Thomas
A Hardy and Vicki
5 -
Atypical Antipsychotics, Neurocognitive Deficits, and
Aggression in Schizophrenic Patients
Krakowski, Menahem I; Czobor, Pal; Nolan, Karen A
Journal of Clinical
Psychopharmacology. 28(5):485-493,
October 2008
3 -
Insulin Resistance and Decreased Glucose-Stimulated Insulin Secretion After Acute Olanzapine
Administration
Chintoh, Araba F; Mann, Steve W;
Lam, Loretta; Lam, Carol; Cohn, Tony A; Fletcher, Paul J; Nobrega,
Jose N; Giacca, Adria;
Remington, Gary
Journal of Clinical
Psychopharmacology. 28(5):494-499,
October 2008
2! -
Second-Generation Antipsychotics in Primary and Secondary Delusional Parasitosis: Outcome and Efficacy
Freudenmann, Roland W; Lepping,
Peter
Journal of Clinical
Psychopharmacology. 28(5):500-508,
October 2008
3! -
Antipsychotics and Oropharyngeal Dysphagia
in Hospitalized Older Patients
Rudolph, James L; Gardner, Kelly F; Gramigna, Gary D; McGlinchey,
Journal of Clinical
Psychopharmacology. 28(5):532-535,
October 2008
3 - A
Randomized, Open-Label Comparison of 2 Switching Strategies to Aripiprazole Treatment in Patients With
Schizophrenia: Add-On, Wait, and Tapering of Previous Antipsychotics Versus
Add-On and Simultaneous Tapering
Takeuchi, Hiroyoshi;
Suzuki, Takefumi; Uchida, Hiroyuki; Nakajima,
Shinichiro; Nomura, Kensuke; Kikuchi, Toshiaki; Manki,
Hiroshi; Watanabe, Koichiro; Kashima, Haruo
Journal of Clinical
Psychopharmacology. 28(5):540-543,
October 2008
4 -
The Temporal Relationship Between Symptom Change and
Treatment Discontinuation in a Pooled Analysis of 4 Schizophrenia Trials
Kinon, Bruce J; Ascher-Svanum, Haya; Adams, David
H; Chen, Lei
Journal of Clinical
Psychopharmacology. 28(5):544-549,
October 2008
3! - Long-Term Antipsychotic Monotherapy for Schizophrenia: Disease Burden and
Comparative Outcomes for Patients Treated With Olanzapine,
Quetiapine, Risperidone, or
Haloperidol Monotherapy in a Pan-Continental
Observational Study
Martin Dossenbach, Jan Pecenak,
Agata Szulc, Victoria Irimia, Martin Anders, Dusanka Logozar-Perkovic, Dalia Peciukaitiene,
Moshe Kotler, Anatoly B. Smulevich,
Teena M. West, Amanda J. Lowry, and Tamas Treuer,
J Clin Psychiatry September 9, 2008: e1-e15
3 - Coregulation of genes in the mouse brain following
treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit
expression in the mechanism of antipsychotic drug action
Duncan, Carlotta E; Chetcuti, Albert F; Schofield,
Peter R
Psychiatric Genetics. 18(5):226-239, October 2008
3 - Twin
study refining psychotic symptom dimensions as phenotypes for genetic research
Alastair G. Cardno, Frühling V. Rijsdijk, Robin M. Murray, Peter McGuffin
3! - A randomised controlled
study of risperidone and olanzapine
for schizophrenic patients with neuroleptic-induced
acute dystonia or parkinsonism
HY Chan, CJ Chang, SC Chiang, JJ Chen, CH Chen, HJ Sun, HG Hwu, and MS Lai
Journal of Psychopharmacology. First published on September 18, 2008
3! - Acute maternal stress in pregnancy and schizophrenia in offspring: A
cohort prospective study
D Malaspina, C Corcoran, KR Kleinhaus,
MC Perrin, S Fennig, D Nahon,
Y Friedlander and S Harlap
3 - Negative symptoms in
schizophrenia—A review
J. Makinen; J. Miettunen; M. Isohanni; H. Koponen
Nordic Journal of
Psychiatry, Volume 62, Issue 5 2008, pages 334 - 341
3 - Schizophrenia and sudden
cardiac death—A review
Hannu Koponen; Antti Alaraisanen; Kaisa Saari; Olavi
Pelkonen; Heikki Huikuri; MJ Pekka Raatikainen; Markku
Savolainen; Matti Isohanni
Nordic Journal of
Psychiatry, Volume 62, Issue 5 2008, pages 342 - 345
3! -
LORETA Functional Imaging in Antipsychotic-Naive and Olanzapine-,
Clozapine- and Risperidone-Treated
Patients with Schizophrenia
Barbora Tislerova, Martin Brunovsky, Jiri Horacek, Tomas Novak, Miloslav Kopecek, Pavel Mohr, Vladimír Krajca
Neuropsychobiology 2008;58:1-10
3 - Mortality among chronic schizophrenic patients: A prospective 14-year
follow-up study of 150 schizophrenic patients
G. Loas,
A. Azi, C. Noisette, V. Yon
L'Encéphale.
Vol 34, No 1: pages 54-60 (janvier 2008)
3! - A Cross-Sectional Study of
Patients' Perspectives on Adherence to Antipsychotic Medication: Depot Versus Oral
Maxine X. Patel, Nicole de Zoysa, Morris Bernadt, and Anthony S. David,
J Clin Psychiatry September 23, 2008: e1-e9
GRATIS 5 - Relative
risk of diabetes, dyslipidaemia, hypertension and the
metabolic syndrome in people with severe mental illnesses. Systematic
review and metaanalysis
David PJ Osborn, Christine A Wright, Gus Levy, Michael B King, Raman Deo and Irwin
5 -
Temporal sequence of clinical manifestation in schizophrenia with co-morbid
OCD: Review and meta-analysis
Kavi K. Devulapalli, Jeffrey A. Welge and
Henry A. Nasrallah
Psychiatry Research. Volume 161, Issue 1, 30 October 2008, Pages 105-108
3 - Predictors of Aripiprazole Treatment Continuation in Hospitalized
Patients
Kim C. Coley, Tanya
J. Fabian, Edward Kim, Diane K. Ammerman,
Tina M. Scipio, Melissa I. Saul, Myoung S. Kim,
Richard Whitehead, and Rohan Ganguli
J Clin Psychiatry
2008;69:1393-1397
3! - Multiple Genetic Factors
in Olanzapine-Induced Weight Gain in Schizophrenia
Patients: A Cohort Study
Hiroshi Ujike, Akira Nomura, Yukitaka Morita,
Akiko Morio, Yuko Okahisa,
Tatsuya Kotaka, Masafumi
Kodama, Takeshi Ishihara, nd Shigetoshi
Kuroda
J Clin Psychiatry
2008;69:1416-1422
3! - Glutamatergic dysfunction
in schizophrenia: From basic neuroscience to clinical psychopharmacology
Rodrigo D. Paz, Sonia Tardito, Marco Atzori
and Kuei Y. Tseng
European
Neuropsychopharmacology. Volume 18, Issue 11,
November 2008, Pages 773-786
3 - Changes
in neuropsychological functioning following treatment with risperidone,
olanzapine, and conventional antipsychotic medications
Jeanette M. Jerrell,
Paul Michael Ramirez
Human Psychopharmacology: Clinical and Experimental. Volume 23 Issue 7, Pages 595 - 604
3! - Cognitive functions in bipolar affective disorder and
schizophrenia: Comparison
Basant K. Pradhan, Subho Chakrabarti, Ritu Nehra, and Anupama Mankotia
Psychiatry and Clinical
Neurosciences. Volume 62 Issue 5, Pages 515 - 525
5 - Is Flunarizine
a Long-Acting Oral Atypical Antipsychotic? A Randomized Clinical Trial Versus Haloperidol for the Treatment of Schizophrenia
Luísa W. Bisol, Miriam G. Brunstein,
Gustavo L. Ottoni, Fernanda
L. P. Ramos, Daniela L. Borba, Claudiane
S. Daltio, Ricardo V. de Oliveira, Gisele E. G. Paz, Sayuri E. de Souza, Rodrigo A. Bressan,
and Diogo R. Lara
J Clin Psychiatry
September 23, 2008: e1-e8
3 - Reversal
of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole
and a 5-HT6 Receptor
Antagonist: Comparison Among Antipsychotics
Joshua S Rodefer, Tuyet N Nguyen,
Jens-Jakob Karlsson and Jørn Arnt
Neuropsychopharmacology (2008) 33, 2657–2666
3 -
Antipsychotic drug mechanisms: links between therapeutic effects, metabolic
side effects and the insulin signaling pathway
R R Girgis, J A Javitch and J
A Lieberman
Molecular
Psychiatry (2008) 13, 918–929
GRATIS 3 - Tratamiento
de la Diskinesia Tardia
Maria Anahi Brizuela
Alcmeon,
Año XVII, Vol. 15, Nº 1, septiembre de 2008, págs. 50 a 81
GRATIS 3 - Long-Term Improvement in Efficacy and Safety After Switching to Ziprasidone in
Stable Outpatients with Schizophrenia
George M. Simpson, Cedric J. O’Gorman, Antony Loebel, and Ruoyong Yang
CNS Spectr. 2008;13(10):898-905
GRATIS 3 - A Review of Repetitive Transcranial Magnetic Stimulation
Use in the Treatment of Schizophrenia
Paul B Fitzgerald, Jeff Daskalakis,
Can J Psychiatry 2008;53(9):567–576
GRATIS 3! - Deficit schizophrenia: an
update
BRIAN KIRKPATRICK and
SILVANA GALDERISI
World
Psychiatry. 2008 October; 7(3): 143–147
GRATIS 3! - Early intervention in
psychosis: concepts, evidence and future directions
PATRICK D. MCGORRY, EÓIN
KILLACKEY, and ALISON YUNG
World
Psychiatry. 2008 October; 7(3): 148–156
| Regresar a RESÚMENES SEPTIEMBRE 2008 |